| Chow, Christopher |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
| Recruiting | 2 | 140 | Europe, Canada, US, RoW | Tirzepatide, Placebo | Eli Lilly and Company, Eli Lilly and Company | Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D | 01/26 | 02/26 | | |
| Neutel, Joel M |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
NCT04776629: A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors |
|
|
| Completed | 2 | 77 | US | Orticumab, MLDL1278a; BI-204; Anti-oxLDL Antibody, Placebo | Abcentra | Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome | 11/22 | 11/22 | | |
BOLD-HTN, NCT06343298: To Evaluate the Safety and Efficacy of MANP in Subjects with Difficult to Control/ Resistant Hypertension |
|
|
| Recruiting | 2 | 132 | US | MANP, Placebo Matched control | E-Star BioTech, LLC, Mayo Clinic, PPD DEVELOPMENT, LP | Difficult to Control Hypertension | 09/25 | 12/25 | | |
NCT04828694: Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections |
|
|
| Completed | 1 | 24 | US | BICX104, Vivitrol | BioCorRx Inc, National Institute on Drug Abuse (NIDA), The HEAL Initiative (https://heal.nih.gov/) | Opioid-use Disorder | 02/23 | 03/23 | | |
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function |
|
|
| Completed | 1 | 16 | US | HM15912 | Hanmi Pharmaceutical Company Limited | Renal Impairment | 08/23 | 08/23 | | |
NCT05611957: A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function |
|
|
| Completed | 1 | 29 | US | LY3437943 | Eli Lilly and Company | Healthy, Renal Insufficiency | 09/23 | 09/23 | | |
NCT06592482: A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 |
|
|
| Recruiting | 1 | 42 | US | AZD0780 | AstraZeneca | Renal Impairment | 01/25 | 01/25 | | |
NCT05395481: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease |
|
|
| Recruiting | 1 | 176 | Japan, US | LY3849891, Placebo | Eli Lilly and Company | Non-Alcoholic Fatty Liver Disease | 12/25 | 12/25 | | |
LORIS-02, NCT05963594: To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO |
|
|
| Completed | N/A | 44 | US | Oligomalt, maltodextrin, Glucidex 40 | Société des Produits Nestlé (SPN) | Dietary Supplement | 03/23 | 03/23 | | |
| Dao, Michael |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
ARGON-2, NCT04378010: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH |
|
|
| Terminated | 2b | 98 | Europe, Canada, US, RoW | EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo | Enanta Pharmaceuticals, Inc | Non-Alcoholic Steatohepatitis | 10/21 | 11/21 | | |
| Chane, Majed |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 300 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 2 | 282 | Canada, US, RoW | JK07, Placebo | Salubris Biotherapeutics Inc | Heart Failure with Reduced Ejection Fraction, Heart Failure with Preserved Ejection Fraction | 12/25 | 06/26 | | |
| Sandoval, Sandra |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
| Active, not recruiting | 2 | 180 | US, RoW | Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent | Zydus Therapeutics Inc. | Nonalcoholic Steatohepatitis, Fibrosis | 07/25 | 07/25 | | |
| Mohseni, Rizwana |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis |
|
|
| Active, not recruiting | 2 | 219 | US | HU6, Placebo | Rivus Pharmaceuticals, Inc. | Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver | 02/25 | 04/25 | | |
| Recruiting | 2 | 48 | US | GSK4532990 | GlaxoSmithKline | Non-alcoholic Fatty Liver Disease | 06/25 | 06/25 | | |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
NCT05864391: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. |
|
|
| Terminated | 1 | 40 | US | AZD7503 | AstraZeneca | Steatohepatitis | 03/24 | 03/24 | | |
NCT06074315: Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis |
|
|
| Recruiting | N/A | 338 | US | Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only) | Nail Genesis LLC | Distal Lateral Subungual Onychomycosis, Onychomycosis | 01/25 | 01/25 | | |
| Jenders, Robert A |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) |
|
|
| Recruiting | 4 | 8600 | US | Naltrexone-Bupropion (NB) Combination, Placebo | Currax Pharmaceuticals | Obesity | 01/29 | 07/29 | | |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH |
|
|
| Completed | 2 | 99 | US | CS0159 (Linafexor), placebo | Cascade Pharmaceuticals, Inc, Laboratory Corporation of America | Nonalcoholic Steatohepatitis (NASH) | 11/23 | 11/23 | | |
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity |
|
|
| Recruiting | 2 | 360 | US, RoW | Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo | Eli Lilly and Company, Regeneron Pharmaceuticals | Obesity | 12/25 | 04/26 | | |
| Recruiting | 2 | 246 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Nonalcoholic Fatty Liver Disease | 09/25 | 12/25 | | |
| Mattar, Peter |
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Active, not recruiting | 3 | 520 | Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 04/25 | 04/25 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT04627272: AutoDx-DR Prospective Clinical Validation Study Protocol |
|
|
| Not yet recruiting | N/A | 1539 | NA | AutoDX-DR | Hill-Rom, Rho, Inc., ClinEdge | Diabetic Retinopathy | 07/21 | 07/21 | | |
| Active, not recruiting | N/A | 626 | US | handheld fundus camera | Digital Diagnostics, Inc., Laboratory Corporation of America | Diabetic Retinopathy | 11/23 | 01/25 | | |
| Koskela, Leesa |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
| Active, not recruiting | 2 | 87 | US | SAP-001, Xanthine Oxidase Inhibitor, Colchicine | Shanton Pharma Pte. Ltd. | Gout | 01/25 | 02/25 | | |
| Bird, Charles David |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Shadd, Maxwell |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
